- Three-year strategic collaboration to leverage InveniAI’s AI- and ML-powered Platform, AlphaMeld® after a profitable proof-of-value collaboration
- AlphaMeld® will seize consumer-specific innovation for each inside and exterior R&D
GUILFORD, Conn., July 29, 2020 (GLOBE NEWSWIRE) — InveniAI® LLC, a world chief in pioneering the appliance of synthetic intelligence (AI) and machine studying (ML) to remodel innovation throughout drug discovery and growth, is happy to announce a strategic collaboration with GlaxoSmithKline Consumer Healthcare, a science-led international healthcare firm with a mission to assist folks to do extra, really feel higher and dwell longer, and one of many world’s main over-the-counter (OTC) medicines firm. GlaxoSmithKline Consumer Healthcare will leverage AlphaMeld®, an AI and ML platform that empowers inside groups to effectively consider and navigate rising innovation spanning the Company’s key focus areas. The three-year collaboration will grant full entry to InveniAI’s AI Innovation Lab that encompasses the Consumer Healthcare Module of AlphaMeld® and an inside workforce of cross-functional consultants to facilitate accelerated entry to innovation.
Michael Keane, Director, Search and Evaluation, GSK Consumer Healthcare, stated, “At GSK Consumer Healthcare, patients and consumers are central to what we do, and it is their needs that drive innovation and product development at GSK. Our heritage in the pharmaceutical industry ensures that all our products are backed with science and associated data. To unlock and prime innovation, we are always listening and engaging with the consumer to ensure that all our products meet a demand. In doing so, the data that we accumulate is large, broad, and complex. InveniAI has helped us look at tasks that are datacentric across technology road-mapping, search and evaluation, and identifying and understanding new science. AI and ML have helped create efficiencies that shave 4-5 years off the innovation cycle as well as eliminate human biases in identifying innovation.”
Aman Kant, InveniAI’s Chief Business Officer, stated, “We are excited about this unique collaboration that will help GSK utilize the power of an AI-driven platform to identify and develop innovative life-changing healthcare products for their consumers. This customized platform delivers tremendous business value by not only rapidly assimilating large volumes of disparate data sets to facilitate a first-mover advantage, but also releases expert human resources at GSK to focus on higher-value tasks. For GSK, the platform enables innovation to be captured as early as patent filing, project funding, or even social media sentiment across several focus areas.” He added, “We are seeing how this technology can provide industries with a tremendous force-multiplier for rapidly sourcing innovation opportunities.”
GSK – a science-led international healthcare firm with a particular goal: to assist folks do extra, really feel higher, dwell longer. For additional data, please go to www.gsk.com.
InveniAI® LLC, primarily based in Guilford, Conn., is a world chief pioneering the appliance of synthetic intelligence (AI) and machine studying (ML) to remodel innovation throughout drug discovery and growth by figuring out and accelerating transformative therapies for illnesses with unmet medical wants. The Company leverages AI and ML to harness petabytes of disparate information units to acknowledge and unlock worth for AI-based drug discovery and growth. Numerous trade collaborations in Big Pharma, Specialty Pharma, Biotech, and Consumer Healthcare showcase the worth of leveraging our know-how to meld human expertise and experience with the facility of machines to reinforce R&D decision-making throughout all main therapeutic areas. The firm leverages the AlphaMeld® platform to generate drug candidates for our trade companions and inside drug portfolio. For extra data, go to www.inveniai.com.
Anita Ganjoo, Ph.D.
T: +1 203 273 8388